Oppenheimer & Co. Inc. Takes $1.29 Million Position in Axsome Therapeutics, Inc. $AXSM

Key Points

• Oppenheimer purchased a new position of 7,076 Axsome shares valued at approximately $1.29 million in the fourth quarter.
• Axsome reported Q1 revenue of $191.2M (up ~57% YoY) driven by AUVELITY and SUNOSI, but missed on GAAP EPS (−$1.26 vs. consensus −$0.85) and showed negative margins and ROE, raising profitability concerns.
• Analyst sentiment is largely positive with multiple price‑target raises and a consensus "Moderate Buy" PT of $251.26, though notable insider selling (~72,628 shares, ≈$12.2M) and ~81.5% institutional ownership could influence near‑term sentiment.

Oppenheimer & Co. Inc. purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,076 shares of the company's stock, valued at approximately $1,292,000.

Other large investors have also bought and sold shares of the company. M&T Bank Corp lifted its holdings in shares of Axsome Therapeutics by 37.3% in the fourth quarter. M&T Bank Corp now owns 2,560 shares of the company's stock worth $467,000 after acquiring an additional 696 shares during the last quarter. Pictet Asset Management Holding SA increased its position in Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company's stock worth $79,643,000 after purchasing an additional 73,925 shares in the last quarter. UBS Group AG lifted its stake in Axsome Therapeutics by 67.2% in the 4th quarter. UBS Group AG now owns 355,318 shares of the company's stock valued at $64,895,000 after purchasing an additional 142,867 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $300,000. Finally, HB Wealth Management LLC grew its stake in shares of Axsome Therapeutics by 136.7% during the fourth quarter. HB Wealth Management LLC now owns 34,102 shares of the company's stock worth $6,228,000 after buying an additional 19,696 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Strong commercial traction — Axsome reported Q1 product revenue of $191.2M, up ~57% year‑over‑year driven by AUVELITY and SUNOSI, which supports the company’s growth narrative and near‑term cash generation. Read More.
• Positive Sentiment: Analyst optimism and price‑target lifts — multiple firms raised targets (notably Mizuho to $310, Wells Fargo to $255, Baird and others), and coverage remains skewed positive, which can support upside momentum and bid interest. Read More.
• Neutral Sentiment: Management outreach scheduled — Axsome will participate in May investor conferences (including a BofA fireside chat), offering additional investor access but uncertain immediate impact. Read More.
• Neutral Sentiment: Earnings detail and call transcript available — analysts are parsing the conference call and guidance implications; deeper read may resolve questions around sales cadence and expense trajectory. Read More.
• Negative Sentiment: Profitability miss — GAAP EPS of ($1.26) missed consensus (~$0.85 loss), and negative margins/ROE highlight near‑term profitability and cost structure concerns despite revenue strength. Read More.
• Negative Sentiment: Insider selling — COO Mark Jacobson disclosed sales (large blocks on May 4 and a smaller sale May 5), which may raise short‑term sentiment questions even though filers report remaining holdings. Read More.
• Negative Sentiment: Durability concerns — some analysts/commentators question sequential product sales trends and achievability of peak revenue assumptions, which could temper multiple expansion absent clearer margin improvements. Read More.

Analyst Ratings Changes

Several research firms recently weighed in on AXSM. Jefferies Financial Group raised their price objective on Axsome Therapeutics from $245.00 to $275.00 and gave the company a "buy" rating in a report on Monday. Cantor Fitzgerald reissued an "overweight" rating and set a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday. Truist Financial raised Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. Oppenheimer set a $280.00 target price on shares of Axsome Therapeutics in a research report on Monday. Finally, Needham & Company LLC boosted their target price on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock a "buy" rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $251.26.

Axsome Therapeutics Trading Down 0.2%

NASDAQ:AXSM opened at $222.63 on Thursday. Axsome Therapeutics, Inc. has a 52 week low of $96.09 and a 52 week high of $234.29. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.48 and a current ratio of 1.39. The firm's fifty day moving average is $172.69 and its 200-day moving average is $164.03. The firm has a market cap of $11.46 billion, a P/E ratio of -59.69 and a beta of 0.59.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.Axsome Therapeutics's revenue was up 57.4% compared to the same quarter last year. Equities analysts expect that Axsome Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Insider Transactions at Axsome Therapeutics

In other news, insider Ari Maizel sold 7,500 shares of the business's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares of the company's stock, valued at $1,368,150. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Mark L. Jacobson sold 35,378 shares of the company's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $161.88, for a total value of $5,726,990.64. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 72,628 shares of company stock valued at $12,205,662. Corporate insiders own 20.60% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.